ES2242856T3 - Antagonistas del ccr5 utiles para el tratamiento del sida. - Google Patents

Antagonistas del ccr5 utiles para el tratamiento del sida.

Info

Publication number
ES2242856T3
ES2242856T3 ES02725381T ES02725381T ES2242856T3 ES 2242856 T3 ES2242856 T3 ES 2242856T3 ES 02725381 T ES02725381 T ES 02725381T ES 02725381 T ES02725381 T ES 02725381T ES 2242856 T3 ES2242856 T3 ES 2242856T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
group
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02725381T
Other languages
English (en)
Spanish (es)
Inventor
Michael W. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2242856T3 publication Critical patent/ES2242856T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ES02725381T 2001-03-29 2002-03-27 Antagonistas del ccr5 utiles para el tratamiento del sida. Expired - Lifetime ES2242856T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29
US279938P 2001-03-29

Publications (1)

Publication Number Publication Date
ES2242856T3 true ES2242856T3 (es) 2005-11-16

Family

ID=23070981

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02725381T Expired - Lifetime ES2242856T3 (es) 2001-03-29 2002-03-27 Antagonistas del ccr5 utiles para el tratamiento del sida.
ES05009882T Expired - Lifetime ES2342942T3 (es) 2001-03-29 2002-03-27 Antagonistas de ccr5 utiles para el tratamiento del sida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05009882T Expired - Lifetime ES2342942T3 (es) 2001-03-29 2002-03-27 Antagonistas de ccr5 utiles para el tratamiento del sida.

Country Status (29)

Country Link
US (5) US6720325B2 (https=)
EP (2) EP1373256B1 (https=)
JP (2) JP4248251B2 (https=)
KR (1) KR100613528B1 (https=)
CN (1) CN100519554C (https=)
AR (1) AR033452A1 (https=)
AT (2) ATE466009T1 (https=)
AU (1) AU2002255947B8 (https=)
BR (1) BR0208398A (https=)
CA (1) CA2442227C (https=)
CZ (1) CZ20032636A3 (https=)
DE (2) DE60204951T2 (https=)
DK (1) DK1373256T3 (https=)
ES (2) ES2242856T3 (https=)
HU (1) HUP0400349A3 (https=)
IL (1) IL157551A0 (https=)
MX (1) MXPA03008853A (https=)
MY (1) MY128609A (https=)
NO (1) NO326349B1 (https=)
NZ (1) NZ527768A (https=)
PE (1) PE20020996A1 (https=)
PL (1) PL364560A1 (https=)
PT (1) PT1373256E (https=)
RU (1) RU2316553C2 (https=)
SI (1) SI1373256T1 (https=)
SK (1) SK287521B6 (https=)
TW (1) TWI237638B (https=)
WO (1) WO2002079194A1 (https=)
ZA (1) ZA200307474B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364560A1 (en) * 2001-03-29 2004-12-13 Schering Corporation Ccr5 antagonists useful for treating aids
KR20040013090A (ko) 2001-07-02 2004-02-11 아스트라제네카 아베 케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
TW200504033A (en) * 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
AU2003300911A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
PE20040769A1 (es) 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
CN1898231B (zh) 2003-11-03 2010-10-27 先灵公司 用作趋化因子受体抑制剂的双六氢吡啶衍生物
EP1725235B1 (en) * 2004-02-05 2009-04-15 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
BRPI0509803A (pt) * 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
EP1790637B1 (en) * 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
AR052865A1 (es) * 2005-01-06 2007-04-11 Schering Corp Preparacion de compuestos farmaceuticos derivados de sales de piperazina
US7728135B2 (en) * 2005-01-06 2010-06-01 Schering Corporation Synthesis of CCR5 receptor antagonists
JP4769257B2 (ja) * 2005-02-23 2011-09-07 シェーリング コーポレイション ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体
EP1858886A1 (en) * 2005-02-23 2007-11-28 Schering Corporation Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
WO2007011293A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
US20100063280A1 (en) * 2006-12-22 2010-03-11 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
EP2259772A2 (en) * 2008-02-29 2010-12-15 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
WO1994018192A1 (en) 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE69623485T2 (de) 1995-06-07 2003-01-09 Kimberly-Clark Worldwide, Inc. Inhibierung von exoprotein in absorbierenden produkten
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
CA2371583C (en) * 1999-05-04 2005-09-13 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
HK1039330B (en) * 1999-05-04 2005-12-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
PL364560A1 (en) * 2001-03-29 2004-12-13 Schering Corporation Ccr5 antagonists useful for treating aids

Also Published As

Publication number Publication date
HUP0400349A3 (en) 2010-03-29
EP1373256A1 (en) 2004-01-02
NO326349B1 (no) 2008-11-17
AU2002255947B8 (en) 2005-11-17
SI1373256T1 (sl) 2005-12-31
HUP0400349A2 (hu) 2004-12-28
JP2008074862A (ja) 2008-04-03
ATE466009T1 (de) 2010-05-15
MXPA03008853A (es) 2003-12-04
ES2342942T3 (es) 2010-07-19
WO2002079194A1 (en) 2002-10-10
CN100519554C (zh) 2009-07-29
MY128609A (en) 2007-02-28
PE20020996A1 (es) 2002-11-01
KR20030083014A (ko) 2003-10-23
RU2003131879A (ru) 2005-05-10
DE60204951D1 (de) 2005-08-11
CN1547580A (zh) 2004-11-17
BR0208398A (pt) 2004-06-15
US20030008877A1 (en) 2003-01-09
SK287521B6 (sk) 2010-12-07
JP4248251B2 (ja) 2009-04-02
US6720325B2 (en) 2004-04-13
CA2442227A1 (en) 2002-10-10
US20060063771A1 (en) 2006-03-23
US20050059666A1 (en) 2005-03-17
CA2442227C (en) 2008-10-28
TWI237638B (en) 2005-08-11
KR100613528B1 (ko) 2006-08-16
US7098213B2 (en) 2006-08-29
NO20034311D0 (no) 2003-09-26
NO20034311L (no) 2003-11-26
PL364560A1 (en) 2004-12-13
US7060701B2 (en) 2006-06-13
HK1057363A1 (en) 2004-04-02
JP2004525157A (ja) 2004-08-19
EP1591444A1 (en) 2005-11-02
SK11962003A3 (sk) 2004-03-02
EP1591444B1 (en) 2010-04-28
RU2316553C2 (ru) 2008-02-10
US20050143390A1 (en) 2005-06-30
US20040157854A1 (en) 2004-08-12
AU2002255947B2 (en) 2005-10-27
ATE299139T1 (de) 2005-07-15
PT1373256E (pt) 2005-11-30
ZA200307474B (en) 2004-12-24
AR033452A1 (es) 2003-12-17
EP1373256B1 (en) 2005-07-06
US7008946B2 (en) 2006-03-07
US6900211B2 (en) 2005-05-31
DK1373256T3 (da) 2005-10-10
IL157551A0 (en) 2004-03-28
HK1083505A1 (en) 2006-07-07
CZ20032636A3 (cs) 2003-12-17
NZ527768A (en) 2005-03-24
DE60204951T2 (de) 2006-05-11
DE60236218D1 (de) 2010-06-10

Similar Documents

Publication Publication Date Title
ES2242856T3 (es) Antagonistas del ccr5 utiles para el tratamiento del sida.
ES2244437T3 (es) Derivados de piperazina utiles como antagonistas de ccr5.
ES2246233T3 (es) Derivados de piperidina utiles como antagonistas de ccr5.
ES2264491T3 (es) Derivados de piperidina utiles como antagonistas de ccr5 para el tratamiento del vih.
AU2002255947A1 (en) CCR5 antagonists useful for treating AIDS
ES2318009T3 (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
TWI331606B (en) Piperidine derivatives useful as ccr5 antagonists
HK1057363B (en) Ccr5 antagonists useful for treating aids
HK1083505B (en) Ccr5 antagonists useful for treating aids
HK1061563B (en) Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv